Drug intelligence / Profile preview

Pfizer-BioNTech COVID-19 Vaccine Bivalent

Development stage: Unknown
Lead developer: BioNTech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular

Overview

The Pfizer-BioNTech COVID-19 Vaccine Bivalent is an mRNA vaccine formulated in lipid nanoparticles. It contains nucleoside-modified mRNA encoding the viral spike glycoprotein of SARS-CoV-2, with components targeting both the original strain and specific Omicron variants (BA.4/BA.5). The vaccine works by delivering mRNA into host cells, which then produce the viral spike protein. This transient expression of the spike antigen induces neutralizing antibody and cellular immune responses against SARS-CoV-2, providing protection against COVID-19. The bivalent formulation was designed to provide broader protection against multiple SARS-CoV-2 variants.

Brand names: Comirnaty Original and Omicron BA.4/BA.5 Bivalent
Other names: Pfizer-BioNTech COVID-19 Vaccine Bivalent

Targets

SARS-CoV-2 spikeHost B-cell receptor and T-cell receptor specific for SARS-CoV-2 spike epitopesACE2 (Angiotensin-converting enzyme 2)

Beyond the preview

Go deeper on Pfizer-BioNTech COVID-19 Vaccine Bivalent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pfizer-BioNTech COVID-19 Vaccine Bivalent.

Explore the full profile